Two Genes That May Help Show How Glioblastoma Tumors Differ
Original title: Integrated Multi-Omics and Radiogenomic Analysis Identifies S100B and ITGB5 as Complementary Candidate Biomarkers of Glioblastoma Heterogeneity.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was an early computer study of existing data, not a test or treatment in people.
The short version
Researchers used computers to find two genes that might one day help doctors understand glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary better.
What was studied. Researchers looked at glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary, a fast-growing brain tumor. They used computer tools to study public data on tumor genes, proteins, cells, and MRI scans.
What they found. Two genes, called S100B and ITGB5, were linked to how long patients lived. S100B seemed to show up widely across the tumor. ITGB5 seemed tied to certain spots, like areas near blood vessels and immune cells, and it showed a different pattern on MRI scans.
What this means, and what it doesn't
What it could mean: These two genes may one day help doctors see how one tumor is different from another. That could help guide future research on tests or treatments.
What it doesn't mean: This is very early work done with computers and existing data. It is not a test or treatment you can get. The researchers say it still needs to be checked in new studies with more patients and more hospitals. It is not a cure.
Source: PubMed, September 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.